MARKETS / NYSE / RMD

NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Resmed Inc. RMD

18 fiscal years on record · USD · FY2025 reported · SEC filings only

5 YEARS OF DIVIDEND GROWTH

Revenue

$5.7B

▲ 9.9% YoY

Net income

$1.5B

▲ 8.8% YoY

Free cash flow

$1.6B

▼ 0.7% YoY

In brief

What this company does

The company offers devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. It employs approximately 11,370 people and sells its products in more than 140 countries through a combination of wholly owned subsidiaries and independent distributors. The company operates in two segments, the Sleep and Breathing Health segment and the Residential Care Software segment. It produces cloud-connected CPAP, automatic positive airway pressure (APAP), bilevel, adaptive servo-ventilation (ASV), and HFT devices that deliver positive airway pressure through a patient interface, either a mask or cannula. Devices accounted for approximately 51% of the company's net revenues in fiscal year 2026. Its Residential Care Software business provides cloud-based solutions to healthcare providers operating in the residential care market, including home medical equipment and home infusion providers, home health and hospice providers, skilled nursing facilities, private duty nursing organizations, senior living facilities, and life plan communities. ResMed Inc., a Delaware corporation, was formed in March 1994 as the ultimate holding company for its operating subsidiaries.

Written from the business description in RESMED INC's annual report to the U.S. Securities and Exchange Commission, filed 13 August 2026. Every sentence was checked against that document before publication.

Growth

USD 5.7B

Revenue, FY2025 · full 18-year series below

Revenue $B Net income $B

FY2025 · Revenue 5.7 · Net income 1.5

Compound annual growth

Revenue

+10.2%

+12.1%

+11.9%

+10.6%

Net income

+19.3%

+26.3%

+15.8%

+13.5%

EPS, diluted

+19.6%

+26.3%

+15.4%

+14.1%

Dividend / share

+10.9%

+9.0%

+7.2%

Returned to shareholders

+55.7%

+33.9%

+14.9%

+19.3%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +12.1% a year over five years — but profit grew faster: net income at +26.3%, earnings per share at +26.3%.

The share count fell from 0.15B to 0.14B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

27 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 33.4% · Net 26.9%

ROE

FY2025 · ROE 24.3%

Gross margin61.1%

Operating margin33.4%

Net margin26.9%

Return on assets17.8%

EBITDAUSD 2.1B

Each USD of equity produced 24 cents of profit this year.

Cash & shareholders

USD 975.2M

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 1.6

Net buybacks $M Dividends $M

FY2025 · Dividends 349.7 · Net buybacks 625.5

Dividends paidUSD 349.7M

Net buybacksUSD 625.5M

Share of profit64.0%

Consecutive raises5 years

USD 349.7M in dividends and USD 625.5M in buybacks — 64% of the year's profit went back to shareholders.

Total assetsUSD 9.0B

EquityUSD 6.6B

CashUSD 1.5B

Gross debtUSD 659.4M

Net debtUSD -809.9M

Current ratio3.10×

The company holds more cash than debt.

The 18-year record

18 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue $B	5.7	5.1	4.7	4.2	3.6	3.2	3.0	2.6	2.3	2.1	1.8	1.7	1.6	1.5	1.4	1.2	1.1	0.9
Operating income $B	1.9	1.7	1.3	1.1	1.0	0.9	0.8	0.6	0.5	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.2	0.2
EBITDA $B	2.1	1.9	1.5	1.3	1.2	1.1	1.0	0.7	0.7	0.5	0.5	0.5	0.5	0.4	0.4	0.3	0.3	0.2
Income tax $B	0.4	0.3	0.2	0.2	0.2	0.4	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Net income $B	1.5	1.4	1.0	0.9	0.8	0.5	0.6	0.4	0.3	0.3	0.4	0.4	0.3	0.3	0.3	0.2	0.2	0.1
Free cash flow $B	1.6	1.7	1.3	0.6	0.2	0.6	0.7	0.4	0.4	0.4	0.5	0.3	0.3	0.3	0.3	0.2	0.1	0.1
EPS, diluted $	10.43	9.51	6.92	6.09	5.30	3.24	4.27	2.80	2.19	2.40	2.49	2.47	2.39	2.10	1.71	1.44	1.23	0.95
Dividend / sh $	2.40	2.12	1.92	1.76	1.68	1.56	1.56	1.48	1.40	1.32	1.20	1.12	1.00	0.68	·	·	·	·
Payout %	23	22	28	29	31	48	36	52	63	54	48	45	41	32	·	·	·	·
ROE %	24.3	25.9	22.7	24.0	25.0	17.6	27.2	19.6	15.7	18.7	21.5	21.1	20.5	19.1	15.3	13.1	·	·
Shares out B	0.14	0.15	0.15	0.15	0.15	0.15	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.14	0.15	0.15	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivitySurgical & Medical Instruments & Apparatus

Listed onNYSE

Incorporated inDelaware

Fiscal year endsJune 30

Data on record since2008